Antitumor effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer

References

• Xiao S, Sun S, Long W, et al. A meta-analytic review of the association between two common SNPs in miRNAs and lung cancer susceptibility. Onco Targets Ther. 2018;11:2419–2427. doi:10.2147/OTT.S15650529750042
   PubMed Web of Science ®Google Scholar
• Damstrup L, Poulsen HS. Review of the curative role of radiotherapy in the treatment of non-small cell lung cancer. Lung Cancer. 1994;11:153–178.7812695
   PubMed Web of Science ®Google Scholar
• Group NM-AC. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26(28):4617–4625. doi:10.1200/JCO.2008.17.716218678835
   PubMedGoogle Scholar
• Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer – is it becoming a reality? Nat Rev Clin Oncol. 2010;7(7):401–414. doi:10.1038/nrclinonc.2010.6420551945
   PubMed Web of Science ®Google Scholar
• Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a canadian multicenter randomized trial. Am Soc Clin Oncol. 1988;6(4):633–641. doi:10.1200/JCO.1988.6.4.633
   PubMed Web of Science ®Google Scholar
• Burdett S, Stewart L, Pignon JP. Chemotherapy in non-small cell lung cancer: an update of an individual patient data-based meta-analysis. J Thorac Cardiovasc Surg. 2005;129(5):1205; author reply 1205–1206. doi:10.1016/j.jtcvs.2004.12.03215867822
   PubMedGoogle Scholar
• Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer. 1995;71:366–370. doi:10.1038/bjc.1995.747530988
   PubMed Web of Science ®Google Scholar
• listed Na. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899–909. doi:10.1136/bmj.311.7010.8997580546
   PubMedGoogle Scholar
• Sun P, Huang W, Jin M, et al. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis. Int J Nanomedicine. 2016;11:4931–4945. doi:10.2147/IJN.S10542727729789
   PubMedGoogle Scholar
• Zhou Y-L, Li Y-M, He W-T. Application of mesenchymal stem cells in the targeted gene therapy for gastric cancer. Curr Stem Cell Res Ther. 2016;11:434–439. doi:10.2174/1574888X1066615102611381826496889
   PubMedGoogle Scholar
• Jin Y, Zhang LZ, Huang Y, Zhang K-N, Xiong B. MiR-182-5p inhibited proliferation and metastasis of colorectal cancer by targeting MTDH. Eur Rev Med Pharmacol Sci. 2018;23:1494–1501.
   Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242. doi:10.1056/NEJMoa01179511807147
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–1037. doi:10.1056/NEJM20010405344140111287972
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–124. doi:10.1056/NEJMoa06504417215529
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Shak S, Fuchs H, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. Massachusetts Med Soc. 2001;344(11):783–792.
   Google Scholar
• Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–480. doi:10.1056/NEJMoa02046112181401
   PubMed Web of Science ®Google Scholar
• Fire A, Xu SQ, Montgomery MK, Kostas SA, Driver SE, Mello C. Potent and specific genetic interference by double-strandedRNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811. doi:10.1038/358889486653
   PubMed Web of Science ®Google Scholar
• Youngren-Ortiz SR, Gandhi NS, España-Serrano L, Chougule MB. Aerosol delivery of siRNA to the lungs. Part 2: nanocarrier-based delivery systems. Kona. 2017;34:44–69. doi:10.14356/kona.201700528392618
   PubMedGoogle Scholar
• Majumder P, Bhunia S, Bhattacharyya J, Chaudhuri A. Inhibiting tumor growth by targeting liposomally encapsulated CDC20siRNA to tumor vasculature: therapeutic RNA interference. J Control Release. 2014;180:100–108. doi:10.1016/j.jconrel.2014.02.01224556418
   PubMed Web of Science ®Google Scholar
• Majumder P, Bhunia S, Chaudhuri A. A lipid-based cell penetrating nano-assembly for RNAi-mediated anti-angiogenic cancer therapy. Chem Commun (Camb). 2018;54(12):1489–1492. doi:10.1039/c7cc08517f29359766
   PubMed Web of Science ®Google Scholar
• Hojat Borna SI, Iman M, Jamalkandi SA. Therapeutic face of RNAi in vivo challenges. Expert Opin Biol Ther. 2014;15(2):1–17. doi:10.1517/14712598.2015.97339825323456
   PubMedGoogle Scholar
• Haussecker D. Current issues of RNAi therapeutics delivery and development. J Control Release. 2014;195:49–54. doi:10.1016/j.jconrel.2014.07.05625111131
   PubMed Web of Science ®Google Scholar
• Nascimento AV, Singh A, Bousbaa H, Ferreira D, Sarmento B, Amiji MM. Mad2 checkpoint gene silencing using epidermal growth factor receptor-targeted chitosan nanoparticles in non-small cell lung cancer model. Mol Pharm. 2014;11(10):3515–3527. doi:10.1021/mp500289425256346
   PubMedGoogle Scholar
• Chung YC, Yeh JY, Tsai CF. Antibacterial characteristics and activity of water-soluble chitosan derivatives prepared by the Maillard reaction. Molecules. 2011;16(10):8504–8514. doi:10.3390/molecules1610850421989311
   PubMed Web of Science ®Google Scholar
• Sun P, Huang W, Kang L, et al. siRNA-loaded poly(histidine-arginine)6-modified chitosan nanoparticle with enhanced cell-penetrating and endosomal escape capacities for suppressing breast tumor metastasis. Int J Nanomedicine. 2017;12:3221–3234. doi:10.2147/IJN.S12943628458542
   PubMed Web of Science ®Google Scholar
• Liu X, Mo Y, Liu X, et al. Synthesis, characterisation and preliminary investigation of the haemocompatibility of polyethyleneimine-grafted carboxymethyl chitosan for gene delivery. Mater Sci Eng C Mater Biol Appl. 2016;62:173–182. doi:10.1016/j.msec.2016.01.05026952412
   PubMed Web of Science ®Google Scholar
• Wang T, Hou J, Su C, Zhao L, Shi Y. Hyaluronic acid-coated chitosan nanoparticles induce ROS-mediated tumor cell apoptosis and enhance antitumor efficiency by targeted drug delivery via CD44. J Nanobiotechnology. 2017;15(1):7. doi:10.1186/s12951-017-0305-228068992
   PubMedGoogle Scholar
• Xiao B, Ma P, Viennois E, Merlin D. Urocanic acid-modified chitosan nanoparticles can confer anti-inflammatory effect by delivering CD98 siRNA to macrophages. Colloids Surf B Biointerfaces. 2016;143:186–193. doi:10.1016/j.colsurfb.2016.03.03527011348
   PubMed Web of Science ®Google Scholar
• Naor D, Sionov RV, Ish-Shalom D. CD44: Structure, Function and Association with the Malignant Process. Cancer Research Vol. 71; 1997:241–319.
   Google Scholar
• Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004;95(12):930–935. doi:10.1111/j.1349-7006.2004.tb03179.x15596040
   PubMedGoogle Scholar
• Thapa R, W GD. The importance of CD44 as a stem cell biomarker and therapeutic target in cancer. Stem Cells Int. 2016;2016:2087204. doi:10.1155/2016/124365927200096
   PubMed Web of Science ®Google Scholar
• Lau WM, Teng E, Chong HS, et al. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res. 2014;74(9):2630–2641. doi:10.1158/0008-5472.CAN-13-230924618343
   PubMedGoogle Scholar
• Quan YH, Kim B, Park J-H, Choi Y, Choi YH, Kim HK. Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44. Exp Lung Res. 2014;40(10):475–484. doi:10.3109/01902148.2014.90565625299431
   PubMed Web of Science ®Google Scholar
• Cortes-Dericks L, Schmid RA. CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives. Respir Res. 2017;18(1):58. doi:10.1186/s12931-017-0546-528403901
   PubMedGoogle Scholar
• Hu B, Ma Y, Yang Y, Zhang L, Han H, Chen J. CD44 promotes cell proliferation in non-small cell lung cancer. Oncol Lett. 2018;15(4):5627–5633. doi:10.3892/ol.2018.805129552200
   PubMedGoogle Scholar
• Schenk RL, Strasser A, Dewson G. BCL-2: long and winding path from discovery to therapeutic target. Biochem Biophys Res Commun. 2017;482(3):459–469. doi:10.1016/j.bbrc.2016.10.10028212732
   PubMed Web of Science ®Google Scholar
• Tsai M-L, Chen R-H, Bai S-W, Chen W-Y. The storage stability of chitosan/tripolyphosphate nanoparticles in a phosphate buffer. Carbohydr Polym. 2011;84(2):756–761. doi:10.1016/j.carbpol.2010.04.040
   Web of Science ®Google Scholar
• Tsai M, Bai S, Chen R. Cavitation effects versus stretch effects resulted in different size and polydispersity of ionotropic gelation chitosan–sodium tripolyphosphate nanoparticle. Carbohydr Polym. 2008;71(3):448–457. doi:10.1016/j.carbpol.2007.06.015
   Web of Science ®Google Scholar
• Nascimento AV, Gattacceca F, Singh A, et al. Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models. Nanomedicine (Lond). 2016;11(7):767–781. doi:10.2217/nnm-2016-023326980454
   PubMedGoogle Scholar
• Li Y, Yang J, Xu B, Gao F, Wang W, Liu W. Enhanced therapeutic siRNA to tumor cells by a pH-sensitive agmatine-chitosan bioconjugate. ACS Appl Mater Interfaces. 2015;7(15):8114–8124. doi:10.1021/acsami.5b0085125832629
   PubMed Web of Science ®Google Scholar
• Chen Y, Gu H, Zhang DS-Z, Li F, Liu T, Xia W. Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier. Biomaterials. 2014;35(38):10058–10069. doi:10.1016/j.biomaterials.2014.09.00325277774
   PubMed Web of Science ®Google Scholar
• Atala A. Re: Mg(II)-catechin nanoparticles delivering siRNA targeting EIF5A2 inhibit bladder cancer cell growth in vitro and in vivo. J Urol. 2017;198(2):258–259.
   Web of Science ®Google Scholar
• Jiang K, Li J, Yin J, et al. Targeted delivery of CXCR4-siRNA by scFv for HER2(+) breast cancer therapy. Biomaterials. 2015;59:77–87. doi:10.1016/j.biomaterials.2015.04.03025956853
   PubMed Web of Science ®Google Scholar
• Somia I. Gene therapy – promises, problems and prospects. Nature. 1997;389(18):239–242. doi:10.1038/384109305836
   PubMedGoogle Scholar
• Merdan T, Kopec̆Ek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev. 2002;54:715–758. doi:10.1016/S0169-409X(02)00046-712204600
   PubMed Web of Science ®Google Scholar
• Huh MS, Lee EJ, Koo H, et al. Polysaccharide-based nanoparticles for gene delivery. Top Curr Chem. 2017;375(2):31. doi:10.1007/s41061-017-0114-y
   Web of Science ®Google Scholar
• Jadidi-Niaragh F, Atyabi F, Rastegari A, et al. Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles. Tumor Biol. 2016;37(6):8403–8412. doi:10.1007/s13277-015-4732-0
   PubMedGoogle Scholar
• Jain A, Thakur K, Sharma G, Kush P, Jain UK. Fabrication, characterization and cytotoxicity studies of ionically cross-linked docetaxel loaded chitosan nanoparticles. Carbohydr Polym. 2016;137:65–74. doi:10.1016/j.carbpol.2015.10.01226686106
   PubMed Web of Science ®Google Scholar
• Huh MS, Lee S-Y, Park S, et al. Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice. J Control Release. 2010;144(2):134–143. doi:10.1016/j.jconrel.2010.02.02320184928
   PubMed Web of Science ®Google Scholar
• Zhong Y, Meng F, Deng C, Zhong Z. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromolecules. 2014;15(6):1955–1969. doi:10.1021/bm500300924798476
   PubMed Web of Science ®Google Scholar
• Ganesh S, Iyer AK, Morrissey DV, Amiji MM. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials. 2013;34(13):3489–3502. doi:10.1016/j.biomaterials.2013.01.07723410679
   PubMed Web of Science ®Google Scholar
• Kankala RK, Chen B-Q, Liu C-G, Tang H-X, Wang S-B, Chen A-Z. Solution-enhanced dispersion by supercritical fluids: an ecofriendly nanonization approach for processing biomaterials and pharmaceutical compounds. Int J Nanomedicine. 2018;13:4227–4245. doi:10.2147/IJN.S16612430087558
   PubMed Web of Science ®Google Scholar
• Kankala RK, Lin X-F, Song H-F, et al. Supercritical fluid-assisted decoration of nanoparticles on porous microcontainers for codelivery of therapeutics and inhalation therapy of diabetes. ACS Biomater Sci Eng. 2018;4(12):4225–4235. doi:10.1021/acsbiomaterials.8b00992
   PubMed Web of Science ®Google Scholar
• Kankala RK, Zhang YS, Wang SB, Lee CH, Chen AZ. Supercritical fluid technology: an emphasis on drug delivery and related biomedical applications. Adv Healthc Mater. 2017;6:16.
   Web of Science ®Google Scholar
• Chen B-Q, Kankala RK, Chen A-Z, et al. Investigation of silk fibroin nanoparticle-decorated poly(l-lactic acid) composite scaffolds for osteoblast growth and differentiation. Int J Nanomedicine. 2017;12:1877–1890. doi:10.2147/IJN.S12952628331312
   PubMed Web of Science ®Google Scholar
• Xu PY, Kankala RK, Pan YJ, Yuan H, Wang SB, Chen AZ. Overcoming multidrug resistance through inhalable siRNA nanoparticles-decorated porous microparticles based on supercritical fluid technology. Int J Nanomedicine. 2018;13:4685–4698. doi:10.2147/IJN.S16939930154654
   PubMed Web of Science ®Google Scholar